Not much was new in DBV Technologies' earnings press release and the several additional management departures are "probably not a huge surprise" given new CEO, Daniel Tasse, recently took the helm, Stifel analyst Derek Archila tells investors in a post-earnings research note. The analyst remains on the sidelines with a Hold rating and $10 price target until management executes on its near-term regulatory initiatives and addresses its current capital overhang. Archila, however, says DBV's risk/reward is "probably more favorable at these levels" if management is able to re-file its biologics license application on time in Q3, gain BLA acceptance from the FDA and its panel meeting is eventually positive.